DEFAR - Departamento de Farmácia

URI permanente desta comunidadehttp://www.hml.repositorio.ufop.br/handle/123456789/530

Navegar

Filtros

2014 - 201912020 - 20231

Configurações

Tem arquivos: SimAssunto: search.filters.subject.Rapid test

Resultados da Pesquisa

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura Disponível
    Item
    Rapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device.
    (2023) Filgueiras, Priscilla Soares; Corsini, Camila Amormino; Almeida, Nathalie Bonatti Franco; Pedrosa, Maria Luysa Camargos; Miranda, Daniel Alvim Pena de; Gomes, Sarah Vieira Contin; Assis, Jéssica Vieira de; Silva, Raphael Antônio; Medeiros, Maria Izabella Vieira de Assis Rocha Carvalho de; Lourenço, Adelina Junia; Bicalho, Cecilia Maria Florencio; Vilela, Raquel Virgínia Rocha; Jeremias, Wander de Jesus; Fernandes, Gabriel da Rocha; Grenfell, Rafaella Fortini Queiroz
    Background: SARS-CoV-2 virus originated in Wuhan (China) in December (2019) and quickly spread worldwide. Antigen tests are rapid diagnostic tests (RDT) that produce results in 15-30 min and are an important tool for the scale-up of COVID-19 testing. COVID-19 diagnostic tests are authorized for self-testing at home in some countries, including Brazil. Widespread COVID-19 diagnostic testing is required to guide public health policies and control the speed of transmission and economic recovery. Methods: Patients with suspected COVID-19 were recruited at the Hospital da Baleia (Belo Horizonte, Brazil). The SARS-CoV-2 antigen- detecting rapid diagnostic tests were evaluated from June 2020 to June 2021 using saliva, nasal, and nasopharyngeal swab samples from 609 patients. Patient samples were simultaneously tested using a molecular assay (RT-qPCR). Sensitivity, specificity, accuracy, and positive and negative predictive values were determined using the statistical program, MedCalc, and GraphPad Prism 8.0. Results: The antigen-detecting rapid diagnostic tests displayed 98% specificity, 60% sensitivity, 96% positive predictive value, and moderate concordance with RT-qPCR. Substantial agreement was found between the two methods for patients tested < 7 days of symptom onset. Conclusions: Our findings support the use of Ag-RDT as a valuable and safe diagnostic method. Ag-RDT was also demonstrated to be an important triage tool for suspected COVID-19 patients in emergencies. Overall, Ag-RDT is an effective strategy for reducing the spread of SARS-CoV-2 and contributing to COVID-19 control.
  • Nenhuma Miniatura Disponível
    Item
    A multicentric evaluation of the recombinant Leishmania infantum antigen-based immunochromatographic assay for the serodiagnosis of canine visceral leishmaniasis.
    (2014) Fraga, Deborah Bittencourt Mothé; Silva, Edimilson Domingos da; Pacheco, Luciano Vasconcellos; Borja, Lairton Souza; Oliveira, Isaac Queiroz de; Vital, Wendel Coura; Monteiro, Glória Regina; Oliveira, Geraldo Gileno de Sá; Jerônimo, Selma Maria Bezerra; Reis, Alexandre Barbosa; Veras, Patrícia Sampaio Tavares
    Background: Visceral leishmaniasis (VL) is a serious public health challenge in Brazil and dogs are considered to be the main urban reservoir of the causative agent. The culling of animals to control VL in some countries makes the accurate diagnosis of canine VL (CVL) essential. Recombinant antigens rLci1A and rLci2B were selected from a cDNA library of Leishmania infantum amastigotes due to their strong potential as candidates in diagnostic testing for CVL. The present multicentric study aimed to evaluate the sensitivity of a prototype test using these antigens (DPPrLci1A/rLci2B) against 154 sera obtained from symptomatic dogs within three endemic areas of VL in Brazil. The specificity was evaluated using 40 serum samples from negative dogs and dogs infected with other pathogens. Sensitivity and specificity rates of DPP rLci1A/rLci2B prototype were compared to rates from other diagnostic tests currently in use by the Brazilian Ministry of Health, including DPP®LVC, EIE®LVC. Findings: DPP rLci1A/rLci2B prototype offered similar performance to that offered by DPP®LVC rapid test, as follows: sensitivity of 87% (CI 81–91) and 88% (CI 82–93) and specificity of 100% (CI 91–100) and 97% (CI 87–100), respectively for DPP rLci1A/rLci2B and DPP®LVC. When results of these two tests were considered concomitantly, sensitivity increased to 93.5% (CI 89–96). Conclusions: The recombinant antigens rLci1A and rLci2B represent promising candidates for use in a multi-antigen rapid test for CVL. The inclusion of novel antigens to the DPP rLci1A/rLci2B prototype model could offer additionally enhanced sensitivity to detect animals infected by L. infantum.